US Bancorp
KERX

US Bancorp’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

US Bancorp’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-32
Closed – – 3708
2016
Q1 		$0 Buy
+32
New +$128 ﹤0.01% 3735
2015
Q4 		– Sell
-3,236
Closed -$11K – 3773
2015
Q3 		$11K Sell
3,236
-34
-1% -$228 ﹤0.01% 3072
2015
Q2 		$33K Sell
3,270
-501
-13% -$5.37K ﹤0.01% 2745
2015
Q1 		$47K Sell
3,771
-6,149
-62% -$79K ﹤0.01% 2570
2014
Q4 		$140K Sell
9,920
-432
-4% -$6.69K ﹤0.01% 1944
2014
Q3 		$142K Buy
10,352
+763
+8% +$11.7K ﹤0.01% 1928
2014
Q2 		$147K Buy
9,589
+6,121
+176% +$86.8K ﹤0.01% 1941
2014
Q1 		$59K Sell
3,468
-124
-3% -$1.87K ﹤0.01% 2410
2013
Q4 		$47K Buy
+3,592
New +$42.9K ﹤0.01% 2447

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

US Bancorp's KERX Position: Q2 2016 in Review

US Bancorp sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 32 shares.

US Bancorp first reported a position in KERX in Q4 2013 and held it in 9 quarters. The position peaked at $147K in Q2 2014. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

  • US Bancorp reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • US Bancorp sold 32 Keryx Biopharmaceuticals Inc shares in Q2 2016.
  • US Bancorp first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 9 quarters.
  • US Bancorp's Keryx Biopharmaceuticals Inc position peaked at $147K in Q2 2014.
  • 118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on US Bancorp's 13F filing for Q2 2016, filed 10 Aug 2016.